




School of Continuous  
Professional Development

# EXHIBITOR PROSPECTUS

10<sup>th</sup> Mayo Clinic Symposium  
on Immuno-Oncology  
and Tumor Microenvironment  
Crosstalk 2024

December 5-7, 2024

Ponte Vedra Inn and Club  
Ponte Vedra Beach, FL  
&via livestream





Dear Exhibitors,

On behalf of the Mayo Clinic School of Continuous Professional Development, I am pleased to invite you to participate in the **10th Mayo Clinic Symposium on Immuno-Oncology and Tumor Microenvironment Crosstalk 2024** that will take place December 5-7, 2024, at the Ponte Vedra Inn and Club in Ponte Vedra Beach, Florida.

Prioritizing and addressing diversity, equity and inclusion in workforce development and organizational culture is essential to providing optimal patient care, achieving health equity, and attracting and engaging the workforce of the future. The course brings together a diverse mix of scientists, clinical experts, and industry partners in the field of tumor microenvironment, immune therapy, anti-angiogenesis and targeted therapy.

This symposium will facilitate the exchange of ideas and new scientific direction involving basic biology and pathways that eventually lead to new individualized therapy for patients. Clinician scientists will present the results of ongoing clinical trials on targeted therapy including immune therapy, anti-angiogenic therapy, and others. Novel genetic and imaging methods to assess alteration of tumor microenvironment for monitoring the effectiveness of therapeutic responses in both pre-clinical and clinical trials will be discussed. Different clinical challenges and benefits of new therapeutic avenues including cardio-oncology will be presented. This symposium will assist in establishing strong collaborations among leading national, international, and Mayo Clinic experts in the field.

We anticipate 150 scientists, oncology specialists, vascular specialists, and industry leaders in Immuno-Oncology (IO) based therapy and other immune therapies to be in attendance.

To view the entire program and additional information please go to <https://ce.mayo.edu/tmeimmunonco2024>.

Sincerely,

**Debabrata Mukhopadhyay, Ph.D.**  
*Professor of Biochemistry and Molecular Biology*  
*Course Director*

**Asher A. Chanan-Khan, M.D., M.B.B.S.**  
*Professor of Medicine*  
*Course Director*

# Dates and Location

## Meeting Date:

Friday, December 5 - 7, 2024

## Meeting Location:

Ponte Vedra Inn and Club  
200 Ponte Vedra Blvd  
Ponte Vedra Beach, FL 32082

## Course Website:

<https://ce.mayo.edu/tmeimmunco2024>

# Planning Committee and Key Contacts

## Planning Committee:

Debabrata Mukhopadhyay, Ph.D.  
Mary Lowell Leary Professor  
Professor of Biochemistry and Molecular Biology  
Course Director  
Mayo Clinic Florida

Asher A. Chanan-Khan, M.D., M.B.B.S  
Professor of Medicine  
Course Co-Director  
Mayo Clinic Florida

## Key Contacts:

Iwona Bukato  
CME Specialist  
Direct Line: 904-953-4770  
E-mail: [Bukato.Iwona@mayo.edu](mailto:Bukato.Iwona@mayo.edu)

Karen Steele  
Education Administrative Coordinator  
Direct Line: 904-953-7904  
E-mail: [Steele.Karen@mayo.edu](mailto:Steele.Karen@mayo.edu)






School of Continuous  
Professional Development

## Conference Highlights

Topics and speakers are carefully chosen to integrate best research with clinical expertise and patient values and promote participation in learning and research activities.

### Agenda Highlights for 2024 include:

- Nanotechnology and System Biology
- Harnessing nano properties to improve cancer immunotherapy
- GBM Microenvironment and novel therapeutics
- Microenvironment and Immune Evasion
- Molecular basis of human diseases
- Microenvironment and Cell Therapy
- Vascular-Immune biology and cell signaling
- Developing precision therapy targeting microenvironment-immune pathways from preclinical to clinical steps





## Why Exhibit?

Technical and educational exhibits provide a professional and educational environment in which physicians can receive demonstrations, view products and services and discuss the clinical uses of these products and services.

### Benefits:

- Interact face-to-face with influential decision makers in the field of neuroscience and oncology
- Build visibility for your company in a competitive marketplace
- Expand your customer base and strengthen existing customer relationships
- Introduce new products and services
- Additional advertisement opportunities to expand reach and further socialize with attendees



School of Continuous  
Professional Development

## EXHIBIT CONTACT

Karen Steele  
*Education Administrative Coordinator*  
*Mayo Clinic School of Continuous Professional Development*  
*4500 San Pablo Rd.*  
*Jacksonville, FL 32224*  
*904-953-7904*  
*E-mail: [Steele.Karen@mayo.edu](mailto:Steele.Karen@mayo.edu)*

## EXHIBIT HALL SCHEDULE

### Exhibit Set-Up


Thursday, December 4, 2024, 4:00 PM – 6:00 PM, ET

### Exhibit Hall

Friday, December 5, 2024  
Saturday, December 6, 2024  
Sunday, December 7, 2024

### Exhibit Tear Down

Sunday, December 7, 2024, 12:30 PM – 1:30 PM, ET





School of Continuous  
Professional Development

## Hotel Accommodations

Located on a stretch of pristine beach in northeast Florida, Ponte Vedra Inn and Club in Ponte Vedra Beach, Florida is the host venue for the 10<sup>th</sup> Mayo Clinic Symposium on Immuno-Oncology and Tumor Microenvironment Crosstalk 2024.

AAA Five-Diamond rated Ponte Vedra Inn & Club is the picture of quiet grandeur, grace, stateliness, and story. Time honored and steeped in 90 years of tradition, the historic Inn & Club successfully combines award-winning accommodations, world-class amenities, and endless activities in a warm and friendly atmosphere





School of Continuous Professional Development

Sponsorship Opportunities	Diamond \$30,000 (Exclusive)	Platinum \$25,000 (Exclusive)	Gold Breakfast \$15,000 Lunch \$18,000	Live Exhibitor \$4,500
Reception, Dinner Sponsor and Virtual Abstract Session December 6, 2024	✓			
Welcome Reception and Virtual Abstract Session December 5, 2024		✓		
Non-CME Promotional Symposium	Breakfast December 6, 2024	Breakfast December 5, 2024	Breakfast December 7, 2024  Lunch December 5, 2024 December 6, 2024	
Complimentary full registration – No CME credit	4	3	2	
Conference Bag Inserts	✓	✓	✓	
Exhibit Table	2- 6 ft. tables (Premium location)	1- 6 ft. tables (Premium location)	1- 6 ft. tables (Premium location)	1- 6 ft. table
Verbal recognition at opening session	✓	✓	✓	✓
Attendee List	✓	✓	✓	✓







School of Continuous  
Professional Development

## Additional Advertisement Opportunities

### **Internet - \$4,000 (Exclusive)**

Help attendees stay connected with their office and home while away. Sponsor the wireless internet access in the meeting space. The supporter will be recognized throughout the meeting in signage and electronic communications

### **Conference Bags - \$3,000 (Exclusive)**

Display your company logo for all Attendees to see and announce your presence at the conference. Your company will provide a high-resolution logo to be printed on conference bags ordered by managing committee. All bags will contain flyers and advertisements from other participants. (Artwork to be provided by sponsoring company and is subject to MCSCPD approval)

### **Lanyards - \$2,000 (Exclusive)**


All attendee badges will be distributed with a lanyard to display the badge throughout the conference. The Lanyard will prominently display your company name and/or logo, whichever you choose. (Artwork to be provided by sponsoring company and is subject to MCSCPD approval)

### **Conference Bag Inserts - \$1,000 (Multiple Opportunities Available)**

Conference bag inserts are a great opportunity to invite attendees to your booth, announce your booth participation or conference-related event. Your company will provide 200 copies of the flyer or advertisement (no larger than 8 ½ x 11, no more than one page) and MCSCPD will stuff them into the official conference bags.

Don't see what you are looking for?

Contact us and we would be happy to discuss additional advertisement opportunities with you.





School of Continuous  
Professional Development

## Terms and Conditions


Exhibitor agrees to abide by ACCME accreditation requirements and ACCME Standards for Integrity and Independence in Accredited Continuing Education (“Standards”) as stated at [www.accme.org/publications/standards-for-integrity-and-independence-accredited-continuing-education](http://www.accme.org/publications/standards-for-integrity-and-independence-accredited-continuing-education).

The standards include, but are not limited to, the following requirements:

- Accredited continuing education must protect learners from commercial bias and marketing.
- Accredited education must be free of marketing or sales of products or services. Faculty must not actively promote or sell products or services that serve their professional or financial interests during accredited education.
- The accredited provider must not share the names or contact information of learners with any ineligible company or its agents without the explicit consent of the individual learner.

Exhibitor may only distribute educational promotional materials at their exhibit space. Distribution of noneducational items (pens, notepads, etc), pharmaceuticals, or product samples is prohibited.

All exhibit fees associated with this activity will be given with the full knowledge of the Accredited Provider. No additional payments, goods, services, or events will be provided to the course director(s), planning committee members, faculty, joint provider, or any other party involved with the activity.



**We look forward to seeing you  
at the Ponte Vedra Inn and Club  
in Ponte Vedra, Florida  
December 5-7, 2024**



## Request for Taxpayer Identification Number and Certification

Go to [www.irs.gov/FormW9](http://www.irs.gov/FormW9) for instructions and the latest information.

**Give form to the  
 requester. Do not  
 send to the IRS.**

**Before you begin.** For guidance related to the purpose of Form W-9, see *Purpose of Form*, below.

<b>Print or type.</b> See <i>Specific Instructions</i> on page 3.	<p><b>1</b> Name of entity/individual. An entry is required. (For a sole proprietor or disregarded entity, enter the owner's name on line 1, and enter the business/disregarded entity's name on line 2.)</p> <p><b>Mayo Clinic Jacksonville</b></p>		
	<p><b>2</b> Business name/disregarded entity name, if different from above.</p>		
	<p><b>3a</b> Check the appropriate box for federal tax classification of the entity/individual whose name is entered on line 1. Check only <b>one</b> of the following seven boxes.</p> <p> <input type="checkbox"/> Individual/sole proprietor                    <input type="checkbox"/> C corporation                    <input type="checkbox"/> S corporation                    <input type="checkbox"/> Partnership                    <input type="checkbox"/> Trust/estate  <input type="checkbox"/> LLC. Enter the tax classification (C = C corporation, S = S corporation, P = Partnership) _____  <b>Note:</b> Check the "LLC" box above and, in the entry space, enter the appropriate code (C, S, or P) for the tax classification of the LLC, unless it is a disregarded entity. A disregarded entity should instead check the appropriate box for the tax classification of its owner.  <input checked="" type="checkbox"/> Other (see instructions)                      <b>501 (c) (3) Tax-exempt Nonprofit Corporation</b> </p>		<p><b>4</b> Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3):</p> <p>Exempt payee code (if any)                      <b>1</b></p> <p>Exemption from Foreign Account Tax Compliance Act (FATCA) reporting code (if any)                                      <b>A</b></p> <p style="text-align: right;"><i>(Applies to accounts maintained outside the United States.)</i></p>
	<p><b>3b</b> If on line 3a you checked "Partnership" or "Trust/estate," or checked "LLC" and entered "P" as its tax classification, and you are providing this form to a partnership, trust, or estate in which you have an ownership interest, check this box if you have any foreign partners, owners, or beneficiaries. See instructions                      <input type="checkbox"/></p>		
	<p><b>5</b> Address (number, street, and apt. or suite no.). See instructions.</p> <p><b>4500 San Pablo Road</b></p>	<p>Requester's name and address (optional)</p>	
	<p><b>6</b> City, state, and ZIP code</p> <p><b>Jacksonville, FL 32224</b></p>		
	<p><b>7</b> List account number(s) here (optional)</p>		

**Part I Taxpayer Identification Number (TIN)**

Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see *How to get a TIN*, later.

<b>Social security number</b>									
-			-						
<b>or</b>									
<b>Employer identification number</b>									
5	9	-	3	3	3	7	0	2	8

**Note:** If the account is in more than one name, see the instructions for line 1. See also *What Name and Number To Give the Requester* for guidelines on whose number to enter.

**Part II Certification**

Under penalties of perjury, I certify that:

- The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and
- I am not subject to backup withholding because (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and
- I am a U.S. citizen or other U.S. person (defined below); and
- The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.

**Certification instructions.** You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and, generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

<b>Sign Here</b>	Signature of U.S. person <i>Katy Domaille</i>	Date 04/25/2024
------------------	--	--------------------

**General Instructions**

Section references are to the Internal Revenue Code unless otherwise noted.

**Future developments.** For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to [www.irs.gov/FormW9](http://www.irs.gov/FormW9).

**What's New**

Line 3a has been modified to clarify how a disregarded entity completes this line. An LLC that is a disregarded entity should check the appropriate box for the tax classification of its owner. Otherwise, it should check the "LLC" box and enter its appropriate tax classification.

New line 3b has been added to this form. A flow-through entity is required to complete this line to indicate that it has direct or indirect foreign partners, owners, or beneficiaries when it provides the Form W-9 to another flow-through entity in which it has an ownership interest. This change is intended to provide a flow-through entity with information regarding the status of its indirect foreign partners, owners, or beneficiaries, so that it can satisfy any applicable reporting requirements. For example, a partnership that has any indirect foreign partners may be required to complete Schedules K-2 and K-3. See the Partnership Instructions for Schedules K-2 and K-3 (Form 1065).

**Purpose of Form**

An individual or entity (Form W-9 requester) who is required to file an information return with the IRS is giving you this form because they



School of Continuous  
Professional  
Development

# 10th Mayo Clinic Symposium on Immuno-Oncology and Tumor Microenvironment Crosstalk 2024

From Novel Therapeutics to  
Transformative Practice



Mark your  
calendar!

**DECEMBER 5-7, 2024**

**Ponte Vedra Inn & Club  
Ponte Vedra Beach, FL**



[ce.mayo.edu/tmeimmuonco2024](https://ce.mayo.edu/tmeimmuonco2024)

# 10th Mayo Clinic Symposium on Immuno-Oncology and Tumor Microenvironment Crosstalk 2024

Mayo Clinic's 10th Annual Symposium on Immuno-Oncology and Tumor Microenvironment Crosstalk brings together scientists, clinical experts and industry partners in the field of tumor microenvironment, immune therapy, anti-angiogenesis and targeted therapy.

This symposium will facilitate the exchange of ideas and new scientific direction involving basic biology and pathways that eventually lead to new individualize therapy for patients. Clinician scientists will present the results of ongoing clinical trials on targeted therapy including immune therapy, anti-angiogenic therapy and others.

---

**Mayo Clinic School of Continuous Professional Development**

ce.mayo.edu | cme@mayo.edu | 800-323-2688

Imagery is copyright Mayo Clinic, Getty Images, Shutterstock or approved for use.

©2024 Mayo Foundation for Medical Education and Research.

MC8200-110SVD

Mayo Clinic  
4500 San Pablo Road  
Jacksonville, FL 32224

ELECTRONIC SERVICE REQUESTED



**DECEMBER 5-7, 2024**

**Ponte Vedra Inn & Club  
Ponte Vedra Beach, FL**

[ce.mayo.edu/tmeimmuonco2024](https://ce.mayo.edu/tmeimmuonco2024)

NON-PROFIT ORG.  
U.S. POSTAGE  
**PAID**  
MAYO CLINIC

**10<sup>th</sup> Mayo Clinic Symposium on Tumor  
Microenvironment and Immuno-Oncology  
Crosstalk:**

***From Novel Therapeutics to transformative practice***

**Ponte Vedra Inn and Club  
Ponte Vedra Beach, Florida**

**December 5-7, 2024**

***All Presentations Eastern Time***

**Thursday, December 5, 2024**

7:00 a.m.	Breakfast, Registration and Exhibits
8:00 a.m.	Section I: Mini-Symposium – Nanotechnology and System Biology Chairs: Priyabrata Mukherjee, Ph.D., Stephenson Cancer Center
8:10 a.m.	Harnessing nano properties to improve cancer immunotherapy. Andrew Wang, M.D., UT Southwestern Medical Center
8:30 a.m.	Discussion
8:35 a.m.	Biomimetic Microbubbles- A Novel Delivery Platform for Immunotherapy and Imaging Ramasamy Paulmurugan, Ph.D., Stanford University
8:55 a.m.	Discussion
9:00 a.m.	Nanoparticles encapsulated with drugs to reduce stenosis formation in hemodialysis vascular access Gaurav Sahai, Ph.D., Oregon State University
9:20 a.m.	Discussion
9:25 a.m.	Title TBA Liangfang Zhang, Ph.D., UC San Diego
9:45 a.m.	Discussion
9:50 a.m.	Title TBA Priyabrata Mukherjee, Ph.D., Stephenson Cancer Center, Oklahoma
10:10 a.m.	Discussion
10:15 a.m.	Coffee Break and Exhibits
10:45 a.m.	Continuous low-dose cancer chemotherapy with oral nanoparticle- paclitaxel Dipanjan Pan, Ph.D., Pennsylvania State University
11:05 a.m.	Discussion
11:10 a.m.	Ex vivo vulnerabilities of human gliomas Sunil Krishnan, M.D., Ph.D., UT Health Houston
11:30 a.m.	Discussion
11:35 a.m.	Title TBA

	Zigang Dong, M.D., Ph.D., China-US(Henan) Hormel Cancer Institute, University of Zhengzhou
11:55 a.m.	Discussion
12:05 p.m.	Lunch
1:15 p.m.	Section II: Welcome and Introduction Cheryl L. Willman, M.D., Mayo Clinic Rochester Alfredo Quiñones-Hinojosa, M.D., Mayo Clinic Florida Vijay Shah, M.D., Mayo Clinic Florida
1:30 p.m.	Section III: GBM Microenvironment and novel therapeutics Chair: Alfredo Quiñones-Hinojosa, M.D., Mayo Clinic Florida
1:35 p.m.	Title TBA Mitchel Berger, M.D., Ph.D., UCSF
1:55 p.m.	Discussion
2:00 p.m.	The critical role of m6A RNA methylation in cancer cell-brain microenvironment interaction and brain metastasis Suyun Huang, M.D., Ph.D., Virginia Commonwealth University
2:20 p.m.	Discussion
2:25 p.m.	Title TBA Panagiotis Z. Anastasiadis, Ph.D., Mayo Clinic Florida
2:45 p.m.	Discussion
2:50 p.m.	Targeting the Development of Resistance to Stem-Cell Active Drugs in Glioblastoma Steven Rosenfeld, M.D., Ph.D., Mayo Clinic Florida
3:10 p.m.	Discussion
3:15 p.m.	Coffee Break and Exhibits
3:45 p.m.	Section IV: Microenvironment and Immune Evasion Chair: Vivek Rangnekar, Ph.D., University of Kentucky
3:50 p.m.	Title TBA Candace Johnson, Ph.D., Roswell Park Cancer Institute
4:10 p.m.	Discussion
4:15 p.m.	Tumor Microenvironment and cellular tracing Nagarajan Kannan, Ph.D., Mayo Clinic Rochester
4:35p.m.	Discussion
4:40 p.m.	Pancreatic cancer tumor microenvironment Daniel D. Billadeau, Ph.D., Mayo Clinic Rochester
5:10 p.m.	Discussion
5:15 p.m.	The good, the bad and the yet to be known about monoclonal anti-CD38 therapy in Multiple Myeloma Fabio Malavasi, M.D., University of Torino Medical School, Torino, Italy
5:35 p.m.	Discussion
5:40 p.m.	Section V: Martin and Winifred Ehlers Lectureship (Named-Professor Lecture) Chair: Jennifer J. Westendorf, Ph.D., Mayo Clinic Rochester
5:45 p.m.	Title TBA



	Guillermo A. Ameer, Sc.D., Daniel Hale Williams Professor of Biomedical Engineering, McCormick School of Engineering, Professor of Surgery, Feinberg School of Medicine
6:10p.m.	Discussion
6:15 p.m.	Section VI: Virtual Poster Session and Networking
7:00 p.m.	Dinner (Supported by Ehlers Lectureship Honoring Dr. Eniola-Adefeso) and Health Disparities in Cancer Research and Care – Gaps and Opportunities Chair: Cheryl L. Willman, M.D., Chair of Biochemistry & Molecular Biology, Mayo Clinic Rochester Panelists: Lewis R. Roberts, M.B., Ch.B., Ph.D., Mayo Clinic Rochester Folakemi T. Odedina, Ph.D., Mayo Clinic Florida Roxana S. Dronca, M.D., Mayo Clinic Florida Candace Johnson, Ph.D., Roswell Park Cancer Institute
9:00 p.m.	ADJOURN – End of Day 1
<b>Friday, December 6, 2024</b>	
7:00 a.m.	Breakfast, Registration and Exhibits
8:00 a.m.	Section VII: Molecular basis of human diseases Chair: Krishnendu Pal, Ph.D., Mayo Clinic Florida
8:10 a.m.	Forkhead (Fox) Transcription Factors in Vascular Formation Tsutomu Kume, Ph.D., Northwestern University
8:30 a.m.	Discussion
8:35 a.m.	Regulation of the PHD/HIF axis in normoxia Resham Bhattacharya, Ph.D., University of Oklahoma
8:55 a.m.	Discussion
9:00 a.m.	Ultrasml silica nanoparticles improve anti-tumor pro-inflammatory and cytotoxic responses in immune suppressive microenvironments. Michelle S. Bradbury, M.D., Ph.D., Memorial Sloan Kettering Institute
9:20 a.m.	Discussion
9:25 a.m.	Pancreatic Cancer and pancreatitis Baoan Ji, Ph.D., Mayo Clinic Florida
9:45 a.m.	Discussion
9:50 a.m.	Neuroblastoma and tumor microenvironment (Young Investigator Talk) Jane Zhu, Ph.D., Mayo Clinic Rochester
10:05 a.m.	Discussion
10:10 a.m.	Coffee Break and Exhibits
10:35 a.m.	Section VIII: Microenvironment and Cell Signaling Chair: Sujit Basu, M.D., Ph.D., Ohio State University
10:40 a.m.	Metabolism and Cancer Edward Chini, M.D., Ph.D., Mayo Clinic Florida
11:00 a.m.	Discussion
11:05 a.m.	Cilia as a biomarker of vascular health

	Ramani Ramchandran, Ph.D., Medical College of Wisconsin
11:25 a.m.	Discussion
11:30 a.m.	Microenvironment Dynamic role in Cancer role Hellmut Augustin, DVM, Ph.D., Heidelberg University
11:50 a.m.	Discussion
11:55 a.m.	Short Talk from Abstract (not accredited)
12:00 p.m.	Lunch
1:00 p.m.	Section IX: Special Keynote Lecture Chair: Asher Chanan-Khan, MD. Mayo Clinic Jacksonville
1:05 p.m.	Title TBA Arul M. Chinnaiyan, M.D., Ph.D., University of Michigan
1:30 p.m.	Discussion
1:35 p.m.	Section X: Microenvironment and Cell Therapy Chair: Hiren Banerjee, M.D., Elizabeth City State University, NC
1:40 p.m.	Title TBA Sanjay Misra, M.D., Mayo Clinic Rochester
2:00 p.m.	Discussion
2:05 p.m.	Endometriosis and Endometrial Cancer: Immune infiltrating cells Khashayarsha Khazaie, Ph.D., D.Sc., Mayo Clinic Arizona
2:25 p.m.	Discussion
2:30 p.m.	TNBC and immune therapy (Young Clinical Investigator Talk) Pooja Advani, M.D., Mayo Clinic Florida
2:45 p.m.	Discussion
2:50 p.m.	Coffee Break and Exhibits
3:20 p.m.	Section XI: Vascular-Immune biology and cell signaling. Chair: Justilien Verline, Ph.D., Mayo Clinic Jacksonville
3:30 p.m.	Liver disease and its microenvironment Vijay Shah, M.D., Mayo Clinic Rochester
3:50 p.m.	Discussion
3:55 p.m.	Pancreatic Cancer and novel therapy Keping Xie, M.D. Ph.D., South China University of Technology School of Medicine
4:15 p.m.	Discussion
4:20 p.m.	Pancreatic Cancer in invasion (Young Investigator Talk) Gina Razidlo, Ph.D., Mayo Clinic Rochester
4:35 p.m.	Discussion
4:40 p.m.	Young Investigator Travel Award Talks from Abstracts (not accredited)
5:00 p.m.	Section XII: Virtual Poster Session and Reception and Dinner with Cultural Program
	ADJOURN – End of Day 2
<b>Saturday, December 7, 2024</b>	
7:00 a.m.	Continental Breakfast, Registration and Exhibits
8:00 a.m.	Section XIII: Developing precision therapy targeting microenvironment-immune pathways from preclinical to clinical steps.

	Chair: Roxana Dronca, M.D., Ph.D., Mayo Clinic Florida
8:10 a.m.	TTFields and pancreatic cancer Hani M. Babiker, M.D., Mayo Clinic Florida
8:30 a.m.	Discussion
8:35 a.m.	Preclinical to Clinical trial in renal cancer Al Copland, Ph.D., Mayo Clinic Florida
8:55 a.m.	Discussion
9:00 a.m.	Title TBA Azra Raza, M.D., Columbia University
9:20 a.m.	Discussion
9:25 a.m.	Title TBA Lewis R. Roberts, M.B., Ch.B., Ph.D., Mayo Clinic Rochester
9:45 a.m.	Discussion
9:50 a.m.	Coffee Break and Exhibits
10:20 a.m.	CAR-T cell therapy in solid tumors Hong Qin, M.D., Ph.D., Mayo Clinic Florida
10:40 a.m.	Discussion
10:45 a.m.	Immune Therapy Clinical Trials and outcomes Keith L. Knutson, Ph.D., Mayo Clinic Florida
11:05 a.m.	Discussion
11:10 a.m.	Section XIV: Folkman Lectureship Forum: New Horizon of Cancer Diagnostic and Therapy Chairs: Alfredo Quiñones-Hinojosa, M.D., Mayo Clinic Florida Vijay Shah, M.D., Mayo Clinic Rochester
11:20 a.m.	Title TBA Chad Mirkin, Ph.D., Northwestern University
11:55 p.m.	Discussion
12:10 p.m.	Overview of the symposium Asher Chanan-Khan, M.D. and Dev Mukhopadhyay, Ph.D., Mayo Clinic Florida
12:20 p.m.	Vote of Thanks Dev Mukhopadhyay, Ph.D., Mayo Clinic Florida
12:30 p.m.	ADJOURN – End of Day 3